Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is
overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory
bowel disease. And it might be more sensitive than FDG in detecting a certain type of
inflammations according to our preliminary research. Thus this prospective study is going to
investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response
assessment and follow-up of inflammatory bowel disease than 18F-FDG PET/CT.